Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis, and oxidative stress.
Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders in elders. Sesamin is a lignan compound and the active constituent of sesame oil with antioxidant and anti-inflammatory properties. This study was carried out to explore the mechanisms underlying sesamin effect against unilateral striatal 6-hydroxydopamine (6-OHDA) model of PD. Intrastriatal 6-OHDA-lesioned rats were pretreated with sesamin at doses of 10 or 20mg/kg/day for one week. Sesamin at a dose of 20mg/kg attenuated motor imbalance in narrow beam test, lowered striatal level of malondialdehyde (MDA) and reactive oxygen species (ROS), improved superoxide dismutase (SOD) activity, lowered striatal caspase 3 activity and α-synuclein expression, attenuated glial fibrillary acidic protein (GFAP) immunoreactivity, depressed nigral neuronal apoptosis, and prevented damage of dopaminergic neurons using tyrosine hydroxylase (TH) immunohistochemistry. These findings reveal the reversal effect of sesamin in 6-OHDA model of PD via attenuation of apoptosis, astrogliosis, oxidative stress, and down-regulation of α-synuclein.
Dept. Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: tmojarad@yahoo.com.
Tourandokht
T
Baluchnejadmojarad
Dept. Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Monireh
M
Mansouri
Dept. Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Jamileh
J
Ghalami
ENT Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Zahra
Z
Mokhtari
Neurophysiology Research Center, Shahed University, Tehran, Iran. Electronic address: mroghani@shahed.ac.ir.
Mehrdad
M
Roghani
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001253:Astrocytes / Q000473:pathology; D001522:Behavior, Animal / Q000187:drug effects; D053148:Caspase 3 / Q000096:biosynthesis; D004149:Dioxoles / Q000494:pharmacology*; D005911:Gliosis / Q000139:chemically induced* / Q000517:prevention & control*; D017705:Lignans / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects*; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D004856:Postural Balance / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism
D004149:Dioxoles; D017705:Lignans; D018696:Neuroprotective Agents; D017382:Reactive Oxygen Species; D008315:Malondialdehyde; D016627:Oxidopamine; D013482:Superoxide Dismutase; C505410:Casp3 protein, rat; D053148:Caspase 3; C054125:sesamin
6-hydroxydopamine; Apoptosis; Astrogliosis; Oxidative stress; Parkinson’s disease; Sesamin